Korro Bio (KRRO) Projected to Post Earnings on Tuesday

Korro Bio (NASDAQ:KRRO) is expected to announce its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect Korro Bio to post earnings of ($1.93) per share and revenue of $0.4250 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 12, 2026 at 7:00 AM ET.

Korro Bio (NASDAQ:KRRO) last released its earnings results on Thursday, March 12th. The company reported ($5.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.93) by ($3.39). The firm had revenue of $1.29 million during the quarter, compared to the consensus estimate of $0.43 million. Korro Bio had a negative return on equity of 115.95% and a negative net margin of 1,834.48%. On average, analysts expect Korro Bio to post $-10 EPS for the current fiscal year and $-10 EPS for the next fiscal year.

Korro Bio Trading Down 4.7%

NASDAQ KRRO opened at $10.40 on Friday. The firm has a market cap of $149.97 million, a PE ratio of -0.83 and a beta of 2.98. The stock has a 50-day moving average of $11.48 and a 200-day moving average of $19.08. Korro Bio has a 1-year low of $5.20 and a 1-year high of $55.89.

Analysts Set New Price Targets

KRRO has been the topic of a number of recent research reports. Wall Street Zen lowered Korro Bio from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. William Blair raised Korro Bio from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Korro Bio in a report on Friday, January 9th. Clear Str raised Korro Bio from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 18th. Finally, Cantor Fitzgerald increased their price target on Korro Bio from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Friday, March 13th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Korro Bio has an average rating of “Moderate Buy” and an average target price of $37.29.

Insiders Place Their Bets

In related news, major shareholder Anthony A. Jr. Florence bought 207,100 shares of the stock in a transaction on Tuesday, March 10th. The stock was bought at an average price of $11.11 per share, for a total transaction of $2,300,881.00. Following the completion of the acquisition, the insider directly owned 1,297,893 shares in the company, valued at approximately $14,419,591.23. This represents a 18.99% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Edward T. Mathers bought 207,100 shares of the company’s stock in a transaction on Tuesday, March 10th. The shares were bought at an average cost of $11.11 per share, for a total transaction of $2,300,881.00. Following the transaction, the insider directly owned 1,297,893 shares in the company, valued at approximately $14,419,591.23. This represents a 18.99% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have purchased 1,656,800 shares of company stock worth $18,407,048. 4.60% of the stock is owned by corporate insiders.

Institutional Trading of Korro Bio

Hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. acquired a new position in shares of Korro Bio during the third quarter worth $39,000. Algert Global LLC acquired a new stake in shares of Korro Bio in the 3rd quarter worth $340,000. Wells Fargo & Company MN boosted its position in shares of Korro Bio by 45.5% in the 4th quarter. Wells Fargo & Company MN now owns 7,522 shares of the company’s stock worth $60,000 after purchasing an additional 2,352 shares in the last quarter. Alliancebernstein L.P. purchased a new position in Korro Bio during the 3rd quarter worth $369,000. Finally, Blair William & Co. IL purchased a new position in Korro Bio during the 3rd quarter worth $467,000. 13.18% of the stock is owned by hedge funds and other institutional investors.

About Korro Bio

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.